Table 2.
Flunixin transdermal solutionb | ||||
---|---|---|---|---|
Yes | No | |||
WS = 1 | Tildipirosina | Yes | 340 | 340 |
No (PSSc) | 340 | 170 | ||
WS > 2 | Tildipirosina | Yes | 340 | 340 |
No (PSSc) | 340 | 170 |
Within the respective stratum, a 2 × 2 factorial (binomial) design was used for assignment to experimental treatment. Two thousand three hundred eighty (2,380) calves were randomly assigned to one of the treatments described below based upon their individual WS at the time of enrollment.
Zuprevo®18% (180 mg tildipirosin/mL) solution; 4 mg tildipirosin/kg (1 mL/cwt) BW, SC.
Banamine Transdermal® (50 mg flunixin meglumine/mL); 3.33 flunixin meglumine/kg (1 mL/15 kg) BW, applied to dorsal midline of back between withers and tailhead.
PSS, Physiologic Saline Solution; 0.9% NaCl; 1 mL/cwt, SC.